PMID- 28195686
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181202
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 125
IP  - 5
DP  - 2017 May
TI  - Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples 
      through a fluorescence in situ hybridization-based assay: Cytological smears 
      versus cell blocks.
PG  - 303-312
LID - 10.1002/cncy.21835 [doi]
AB  - Anaplastic lymphoma kinase (ALK) status analysis of lung cytological specimens 
      should be successfully encouraged in routine practice because biopsy specimens 
      are not always available. To date, the US Food and Drug Administration has 
      approved both fluorescence in situ hybridization (FISH) and immunohistochemistry 
      (IHC) as diagnostic tests for identifying ALK-positive patients eligible for 
      treatment with crizotinib. Although ALK IHC is an optimal diagnostic tool, FISH 
      becomes mandatory in equivocal cases. ALK FISH of paraffin-embedded tissue 
      material is still the gold standard, whereas the cytological specimen assay has 
      not yet been completely standardized. Many controversial data have been reported 
      on the adequacy of cytology cell blocks (CBs) versus conventional smears for FISH 
      testing. This review discusses some critical issues related to ALK FISH of 
      cytological samples, including the triaging of collected specimens to optimize 
      the material, the use of CBs versus conventional smears, and alternative methods 
      for an ALK rearrangement diagnosis. Conventional smears have the advantages of an 
      immediate evaluation, no probe tissue-related artifactual loss, no 
      fixation-related alterations, and usually sufficient material for an analytic 
      preparation. On the other hand, CBs have several advantages, including the 
      appropriate conservation of the tissue architecture, an absence of problems 
      related to cell overlapping, and the ability to evaluate neoplastic cells in a 
      dark field. Cancer Cytopathol 2017;125:303-312. (c) 2017 American Cancer Society.
CI  - (c) 2017 American Cancer Society.
FAU - Zito Marino, Federica
AU  - Zito Marino F
AD  - Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
AD  - Pathology Unit, Luigi Vanvitelli University of Campania, Naples, Italy.
FAU - Rossi, Giulio
AU  - Rossi G
AD  - Unit of Pathologic Anatomy, Azienda USL Valle d'Aosta, Aosta, Italy.
FAU - Brunelli, Matteo
AU  - Brunelli M
AD  - Anatomic Pathology Section Department of Pathology, University of Verona, Verona, 
      Italy.
FAU - Malzone, Maria Gabriella
AU  - Malzone MG
AD  - Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
FAU - Liguori, Giuseppina
AU  - Liguori G
AD  - Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
FAU - Bogina, Giuseppe
AU  - Bogina G
AD  - Section of Pathologic Anatomy, Sacro Cuore Don Calabria Hospital, Negrar, Italy.
FAU - Morabito, Alessandro
AU  - Morabito A
AD  - Medical Oncology Unit, Department of Thoracic Surgical and Medical Oncology, 
      Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
FAU - Rocco, Gaetano
AU  - Rocco G
AD  - Division of Thoracic Surgery, Department of Thoracic Surgical and Medical 
      Oncology, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
FAU - Franco, Renato
AU  - Franco R
AD  - Pathology Unit, Luigi Vanvitelli University of Campania, Naples, Italy.
FAU - Botti, Gerardo
AU  - Botti G
AD  - Pathology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20170214
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/diagnosis/drug therapy/*genetics
MH  - Anaplastic Lymphoma Kinase
MH  - Crizotinib
MH  - Cytodiagnosis/methods
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/diagnosis/drug therapy/*genetics
MH  - Paraffin Embedding
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyrazoles/therapeutic use
MH  - Pyridines/therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Specimen Handling
OTO - NOTNLM
OT  - anaplastic lymphoma kinase (ALK)
OT  - cell block
OT  - cytological smears
OT  - fluorescence in situ hybridization (FISH)
OT  - lung cytology
EDAT- 2017/02/15 06:00
MHDA- 2017/08/15 06:00
CRDT- 2017/02/15 06:00
PHST- 2016/10/11 00:00 [received]
PHST- 2016/12/15 00:00 [revised]
PHST- 2016/12/19 00:00 [accepted]
PHST- 2017/02/15 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2017/02/15 06:00 [entrez]
AID - 10.1002/cncy.21835 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2017 May;125(5):303-312. doi: 10.1002/cncy.21835. Epub 2017 
      Feb 14.